Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 7200 participants.
Also called NCT01433627
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,200 participants
- Registry
-
NCT01433627 -
2011-000430-11
-
- Other papers using this trial's data
- Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management
- Acute kidney injury after percutaneous coronary intervention: Rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study
- Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial
- Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes
- Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes
- Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest
- Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial
- Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome
- Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes
- Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome
- Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
- Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial
- Ultra-Short Term Evaluation of Coronary Vessel Wall Changes in Reference Segments Adjacent to Culprit Lesions in ST-Segment Elevation Myocardial Infarction
- Validation of the Mayo Clinic Percutaneous Coronary Intervention Risk Prediction Score in Patients With Acute Coronary Syndrome
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Italy
- Registry status
- Unknown status
Technical summary
Registry record NCT01433627. Randomized; single masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2014-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
- Acronym
- MATRIX
- Condition
- Acute Coronary Syndromes
- Condition
- STEMI
- Condition
- NSTEMI
- Intervention (Other)
- trans-radial and short-term bivalirudin
- Intervention (Other)
- trans-radial and long-term bivalirudin infusion
- Intervention (Other)
- trans-radial and standard of care pharmacology
- Intervention (Other)
- Trans-femoral and Short-term bivalirudin
- Intervention (Other)
- trans-femoral and long-term bivalirudin infusion
- Intervention (Other)
- trans-femoral and standard of care pharmacology
- Lead sponsor
- Italian Society of Invasive Cardiology
- Collaborator
- Eustrategy
Record details
- Record id
cardio:ct-nct01433627- Content hash
bd213ae1d3b77a1a1182f0c448ec7b1645187416791af9c62741db75c15bd241